Edwards Lifesciences (EW) Cash & Current Investments (2009 - 2026)

Edwards Lifesciences has reported Cash & Current Investments for 18 years, with the latest figure at $4.3 billion in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 4.69% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $4.3 billion, a 4.69% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, up 6.3% from the prior year.
• Cash & Current Investments was $4.3 billion for Q2 2026 at Edwards Lifesciences, up from $3.7 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $4.4 billion in Q3 2024, with the low at $1.2 billion in Q4 2022.
• Average Cash & Current Investments over 5 years is $2.7 billion, with a median of $1.9 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments declined 17.15% in 2022, then soared 143.5% in 2024.
• Over 5 years, Cash & Current Investments stood at $1.2 billion in 2022, then surged by 34.35% to $1.6 billion in 2023, then jumped by 143.5% to $4.0 billion in 2024, then gained by 6.3% to $4.2 billion in 2025, then climbed by 0.62% to $4.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $4.3 billion (Q2 2026), $3.7 billion (Q1 2026), and $4.2 billion (Q4 2025), per Business Quant data.